BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially launched its fully human heavy chain antibody platform, RenNano®. RenNano® is the third member of the RenMice™ family, joining RenMab™ and RenLite®. Together, Biocytogen’s three RenMice™ platforms allow for the streamlined discovery and development of fully human monoclonal antibodies, bispecific/multispecific antibodies and single-domain antibodies (sdAbs, or nanobodies) (Figure 1).
While humans and mice generate antibodies that require heavy and light chain pairing to be functional, camels and sharks generate heavy-chain-only antibodies (HCAb), meaning their variable domains (VHH or sdAb) can function without pairing with the light chain. Owing to their nanometer-level size and small molecular weight, sdAbs have superior permeability, and thus can cross the blood-brain barrier and infiltrate solid tumor tissues. In addition, the longer CDR3 region enables sdAbs to detect the otherwise hidden epitopes of GPCRs and other challenging targets. Since sdAbs have a simple structure, they are ideal building blocks for assembling bispecific/multispecific antibodies and CAR cell therapies.
While nanobodies have its unique advantages, animals that naturally produce HCAbs, such as camels, are difficult to be widely used for the preparation of monoclonal antibodies because they are large, having a long breeding cycle and generate few offspring. Meanwhile, humanization is required to develop camelid antibody sequences into drugs, which further increases the complexity and time of drug development.
To overcome these challenges, Biocytogen engineered the RenNano® mouse by modifying the constant region of the fully human RenMab™ model to allow for HCAb production. Compared with other existing HCAb platforms, the in situ replacement of the mouse genes with the complete human heavy chain variable genes makes the RenNano® mouse one of the most comprehensive fully human antibody platforms in the world. SdAb sequences generated from RenNano® mice have the highest possible diversity, and do not require antibody humanization, which saves time and cost, and reduces risk of failure during later stages of drug development. Additionally, compared with camelids or other natural HCAb-producing species, mice are easier to breed and immunize. Immunization of RenNano® mice can generate HCAbs with diverse CDR3 sequences that recognize a variety of epitopes. These HCAbs can recognize antigens with nM-level affinity independent of light chains. Moreover, antibodies derived from RenNano® mice are capable of exerting biological functions both in vitro and in vivo. They are highly hydrophilic and have favorable developability characteristics.
The successful development of the RenNano® platform expands Biocytogen’s capabilities for antibody discovery and broadens the applications of our antibody library. We welcome global partners to realize the full potential of our RenMice™ platforms and derive antibodies to generate novel therapeutics.
About RenMice
RenMice™, i.e., RenMab™, RenLite® and RenNano® mice, which have proprietary intellectual property rights, were developed by Biocytogen over the course of 5 years using size-unlimited, precise chromosome engineering technology (SUPCE). RenMice™ is one of the top 3 fully human antibody mice made by in situ replacement technology globally. All RenMice™ members contain full human heavy chain VDJ loci replaced in situ. Regarding antibody κ light chains, RenMab™ mouse contains full human VJ loci replaced in situ and RenLite® mouse contains a single human VJ locus replaced in situ. RenNano® mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice™ can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. Using RenMice™, Biocytogen has built 6 fully human antibody discovery platforms, covering various types of targets and modalities such as monoclonal antibody (RenMab™), bispecific antibody and bispecific ADC (RenLite®), nanobody (RenNano®), TCR-mimic antibody for intracellular targets (HLA/RenMice, humanized RenMice™), and antibody platform against GPCR and other challenging targets (RenMice™ knockouts).
RenMice™ has been recognized by top biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen:
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005963/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final Hearings on Aviator LLC’s IP Dispute to Be Heard in Georgian Court of Appeals on February 145.2.2025 15:25:00 CET | Press release
After reaching settlement with Flutter Entertainment Plc, Aviator LLC is continuing to pursue litigation against SPRIBE OU regarding IP infringement and legal ownership claims of the brand Aviator. Previously Georgia’s Court of First Instance has issued a judgment invalidating SPRIBE’s trademarks in Georgia, finding that SPRIBE registered disputed trademarks in bad faith and in breach of Aviator LLC’s copyrights. Factual Background The original Avaitor logo was created by the designer Mr. Giorgi Popiashvili in 2017 and was used by the land casino operator Aviator in Georgia since 2018. Casino Aviator was owned by Teumraz Ugulava and was operating under the premises of Stamba Hotel, also owned by him. The same logo was used for online roulette streaming on one of the biggest online gambling platforms in Georgia, called Adjarabet (www.adjarabet.com). At the time, this platform was also owned by Mr. Ugulava who was running Adjarabet under the company Aviator LLC, established in 2015. In 2
Tigo Energy Drive Towards Total Quality Solar Pays off With 1,000-System Green Glove Milestone5.2.2025 15:00:00 CET | Press release
Tigo Green Glove milestone covers installations on four continents, delivering comprehensive support to Commercial & Industrial (C&I) customers, and is expanding for residential installers. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” “Company”), a leading provider of intelligent solar and energy software solutions, today announced solar installers across four continents have enrolled more than 1,000 systems in the Tigo Green Glove program. Designed by Tigo as one of the main pillars to deliver Total Quality Solar (TQS) through comprehensive support at every stage of solar system deployment, the Green Glove program has rapidly become a vital resource for solar installers, driving faster design and deployment, higher-quality installations, inbuilt first-responder safety, and improved system performance and reliability. While nearly 70% of Green Glove engagements have come from the C&I sector, providing proactive quality assurance in larger, more complex solar installations, Tigo is now acti
Global CIO Study Reveals ROI Remains Greatest AI Adoption Barrier, Despite Three-Fold Spend Increase5.2.2025 15:00:00 CET | Press release
Lenovo-commissioned research reveals forty-two percent of global organizations plan to institutionalize Generative AI use casesThirty-seven percent of management remains skeptical toward AI Business leaders and IT decision-makers confirm AI use will reach mainstream levels of adoption as organizations devote a greater slice of their IT budgets to AI implementations, according to new IDC research commissioned by Lenovo. The new global 2025 CIO Playbook entitled It’s Time for AI-nomics, highlights AI spending expectations by IT decision-makers globally to nearly triple in 2025 compared with last year. But critical challenges include uncertain financial returns on these investments and gaps in organizational readiness. Proving ROI: The Greatest Barrier While most AI use cases have met business expectations, proving the return of these investments remains challenging—financial risk and uncertain ROI rank as the greatest barriers to AI adoption. This tension is magnified by a disconnect bet
Datassential Expands Global Menu and Limited-Time Offer Data Across Europe’s Big 5 Markets5.2.2025 14:30:00 CET | Press release
Datassential, the leading food and beverage intelligence platform connecting the dots between consumers and the industry, has announced the expansion of its cutting-edge global sales intelligence solution to include in-depth menu and limited-time offer (LTO) tracking across Europe’s Big 5 markets: France, Germany, Italy, Spain, and the U.K. This enhancement further solidifies Datassential’s position as the gold standard for empowering the foodservice ecosystem with actionable insights. With a foodservice prospecting platform tracking more than 11 million operators across 70+ countries and 100+ operator attributes, Datassential’s solution offers unparalleled tools to increase sales productivity and win rates. The addition of comprehensive menu data in these key European markets gives users access to deep insights, enabling smarter, data-driven menu recommendations tailored to operators' diverse needs. “Understanding global menus and limited-time offers has never been more critical for o
Celonis Research Unveils: 89% of Business Leaders say AI Without Process Intelligence Fails to Deliver Expected Results5.2.2025 10:00:00 CET | Press release
The vast majority of decision makers surveyed (89%) said AI needs to have the context of how their business runs to deliver the expected results.81% of respondents said their companies plan to use AI specifically to improve business processes in the next 12 months.The majority (58%) of leaders worry that process shortcomings may limit AI’s contribution to their business. Celonis, the global leader in Process Mining and Process Intelligence, today released survey findings that demonstrate widespread recognition that AI requires Process Intelligence to be effective and relevant for the business. With Celonis Process Intelligence, AI gains the context it needs to understand how a business runs and how to make it run better. The 2025 Process Optimization Report shows that the vast majority of enterprise leaders (89%) say it’s crucial that AI has the context of how their business runs if it is going to deliver meaningful results and increase operational efficiency. The majority (58%) worry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom